{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:56:22Z","timestamp":1791003382541,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Brittany Dulmage is funded by a Dermatology Foundation Career Development Award."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Opinion Statement<\/jats:title>\n          <jats:p>Cancer-related alopecia (CRA) presents a significant challenge for many patients undergoing cancer treatment, often affecting their psychological well-being and sense of identity. In my opinion, the optimal management of CRA requires a proactive, personalized approach that prioritizes both prevention and regrowth, while taking into account the type of cancer therapy, patient goals, and overall clinical context. For patients receiving chemotherapy, especially taxane- or anthracycline-based regimens, scalp cooling should be offered as a first-line preventative option whenever feasible. Its demonstrated effectiveness, particularly when appropriately sequenced with chemotherapy agents, makes it a valuable tool in preserving hair and quality of life. For patients with contraindications to scalp cooling or limited access to this intervention, early counseling and support around hair loss expectations and coping strategies remain critical. In terms of regrowth, topical minoxidil remains the most evidence-based pharmacologic option and should be recommended, especially for patients with endocrine therapy- or chemotherapy-induced alopecia. While oral minoxidil shows promise, it should be used with caution until more robust safety data are available in oncology settings. Spironolactone, tretinoin, prostaglandin analogs, and red light therapy may be considered in select cases, especially when standard options are insufficient, though patients should be counseled on the limitations of available evidence. Ultimately, a patient-centered, multidisciplinary approach is key to optimizing outcomes in CRA care.<\/jats:p>","DOI":"10.1007\/s11864-025-01336-2","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T10:42:05Z","timestamp":1752489725000},"page":"706-715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cancer-Related Alopecia Risk and Treatment"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8761-3162","authenticated-orcid":false,"given":"Lily","family":"Kaufman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2318-5488","authenticated-orcid":false,"given":"Lilia","family":"Valentic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2741-3951","authenticated-orcid":false,"given":"Hannah","family":"Moulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3043-8903","authenticated-orcid":false,"given":"Brittany","family":"Dulmage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"4","key":"1336_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/pon.1245","volume":"17","author":"J Lemieux","year":"2008","unstructured":"Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology. 2008;17(4):317\u201328. https:\/\/doi.org\/10.1002\/pon.1245.","journal-title":"Psychooncology"},{"issue":"12","key":"1336_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/j.1346-8138.1998.tb02507.x","volume":"25","author":"R Paus","year":"1998","unstructured":"Paus R. Principles of hair cycle control. J Dermatol. 1998;25(12):793\u2013802. https:\/\/doi.org\/10.1111\/j.1346-8138.1998.tb02507.x.","journal-title":"J Dermatol"},{"issue":"7","key":"1336_CR3","first-page":"5","volume":"15","author":"RM Tr\u00fceb","year":"2010","unstructured":"Tr\u00fceb RM. Chemotherapy-induced hair loss. Skin Therapy Lett. 2010;15(7):5\u20137.","journal-title":"Skin Therapy Lett"},{"key":"1336_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/bs.podrm.2018.11.001","volume":"44","author":"FY Alqahtani","year":"2019","unstructured":"Alqahtani FY, Aleanizy FS, El Tahir E, Alkahtani HM, AlQuadeib BT. Paclitaxel. Profil Drug Subst Excip Relat Methodol. 2019;44:205\u201338. https:\/\/doi.org\/10.1016\/bs.podrm.2018.11.001.","journal-title":"Profil Drug Subst Excip Relat Methodol"},{"key":"1336_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110214","volume":"119","author":"R Gupta","year":"2023","unstructured":"Gupta R, Kadhim MM, Turki Jalil A, Qasim Alasheqi M, Alsaikhan F, Khalimovna Mukhamedova N, et al. The interactions of docetaxel with tumor microenvironment. Int Immunopharmacol. 2023;119: 110214. https:\/\/doi.org\/10.1016\/j.intimp.2023.110214. (Highlights evolving understanding of taxane-chemotherapy interaction with the tumor microenvironment, contributing to mechanistic insights into hair follicle vulnerability).","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"1336_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1684\/ejd.2016.2833","volume":"26","author":"V Sibaud","year":"2016","unstructured":"Sibaud V, Leb\u0153uf NR, Roche H, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016;26(5):427\u201343. https:\/\/doi.org\/10.1684\/ejd.2016.2833.","journal-title":"Eur J Dermatol"},{"issue":"15","key":"1336_CR7","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","volume":"332","author":"EK Rowinsky","year":"1995","unstructured":"Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332(15):1004. https:\/\/doi.org\/10.1056\/NEJM199504133321507.","journal-title":"N Engl J Med"},{"issue":"2","key":"1336_CR8","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","volume":"14","author":"R Paus","year":"2013","unstructured":"Paus R, Haslam IS, Sharov AA, Botchkarev VA. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 2013;14(2):e50\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(12)70553-3.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1336_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jaad.2009.06.063","volume":"63","author":"B Tallon","year":"2010","unstructured":"Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol. 2010;63(2):333\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2009.06.063.","journal-title":"J Am Acad Dermatol"},{"key":"1336_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1146\/annurev-pharmtox-022823-035521","volume":"64","author":"RB Cejas","year":"2024","unstructured":"Cejas RB, Petrykey K, Sapkota Y, Burridge PW. Anthracycline toxicity: light at the end of the tunnel? Annu Rev Pharmacol Toxicol. 2024;64:115\u201334. https:\/\/doi.org\/10.1146\/annurev-pharmtox-022823-035521. (Provides a contemporary review of anthracycline toxicity, including mechanisms relevant to hair follicle damage. Useful for contextualizing alopecia within broader toxicity).","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"1336_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-018-0547-8","volume":"19","author":"S Jasra","year":"2018","unstructured":"Jasra S, Anampa J. Anthracycline use for early stage breast cancer in the modern era: a review. Curr Treat Options Oncol. 2018;19(6): 30. https:\/\/doi.org\/10.1007\/s11864-018-0547-8.","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"1336_CR12","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","volume":"80","author":"A Freites-Martinez","year":"2019","unstructured":"Freites-Martinez A, Shapiro J, Goldfarb S, et al. Hair disorders in patients with cancer. J Am Acad Dermatol. 2019;80(5):1179\u201396. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.055.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1336_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","volume":"27","author":"CM Walko","year":"2005","unstructured":"Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23\u201344. https:\/\/doi.org\/10.1016\/j.clinthera.2005.01.005.","journal-title":"Clin Ther"},{"issue":"4","key":"1336_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/jocd.12308","volume":"16","author":"A Rossi","year":"2017","unstructured":"Rossi A, Fortuna MC, Caro G, et al. Chemotherapy-induced alopecia management: clinical experience and practical advice. J Cosmet Dermatol. 2017;16(4):537\u201341. https:\/\/doi.org\/10.1111\/jocd.12308.","journal-title":"J Cosmet Dermatol"},{"issue":"6","key":"1336_CR15","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","volume":"154","author":"A Freites-Martinez","year":"2018","unstructured":"Freites-Martinez A, Shapiro J, Chan D, et al. Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol. 2018;154(6):670\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2018.0454.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1336_CR16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","volume":"18","author":"V Saggar","year":"2013","unstructured":"Saggar V, Wu S, Dickler MN, Lacouture ME. Alopecia with endocrine therapies in patients with cancer. Oncologist. 2013;18(10):1126\u201334. https:\/\/doi.org\/10.1634\/theoncologist.2013-0193.","journal-title":"Oncologist"},{"issue":"3","key":"1336_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10549-024-07440-5","volume":"208","author":"AM Kuo","year":"2024","unstructured":"Kuo AM, Reingold RE, Ketosugbo KF, et al. Oral minoxidil for late alopecia in cancer survivors. Breast Cancer Res Treat. 2024;208(3):491\u20139. https:\/\/doi.org\/10.1007\/s10549-024-07440-5. (One of few studies exploring oral minoxidil in cancer survivors with persistent alopecia, offering evidence for regrowth where data is otherwise limited).","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1336_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annder.2022.11.013","volume":"150","author":"V Sibaud","year":"2023","unstructured":"Sibaud V, Sollena P. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: an updated review for clinical practice. Ann Dermatol Venereol. 2023;150(3):208\u201312. https:\/\/doi.org\/10.1016\/j.annder.2022.11.013.","journal-title":"Ann Dermatol Venereol"},{"issue":"3","key":"1336_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1505270. (Summarizes updated clinical findings in CDK 4\/6 inhibitor-induced skin toxicities, including alopecia\u2014an important emerging side effect in targeted therapies).","journal-title":"N Engl J Med"},{"issue":"4","key":"1336_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2174\/1389557522666220606095540","volume":"23","author":"MA Hassan","year":"2023","unstructured":"Hassan MA, Ates-Alagoz Z. Cyclin-dependent kinase 4\/6 inhibitors against breast cancer. Mini Rev Med Chem. 2023;23(4):412\u201328. https:\/\/doi.org\/10.2174\/1389557522666220606095540. (Describes CDK 4\/6 inhibitors in oncology and supports mechanistic understanding of hair loss related to these agents).","journal-title":"Mini Rev Med Chem"},{"issue":"7","key":"1336_CR21","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(18)30292-4.","journal-title":"Lancet Oncol"},{"issue":"20","key":"1336_CR22","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1607303.","journal-title":"N Engl J Med"},{"issue":"2","key":"1336_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40257-021-00645-0","volume":"23","author":"E Raschi","year":"2022","unstructured":"Raschi E, Fusaroli M, La Placa M, et al. Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system. Am J Clin Dermatol. 2022;23(2):247\u201355. https:\/\/doi.org\/10.1007\/s40257-021-00645-0. (Uses FDA safety data to identify signal strength for CDK 4\/6 inhibitor-induced alopecia, helping quantify real-world incidence.).","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1336_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08160-0","volume":"31","author":"A Minta","year":"2023","unstructured":"Minta A, Rose L, Park C, et al. Retrospective cohort study of CDK4\/6-inhibitor-induced alopecia in breast cancer patients. Support Care Cancer. 2023;31(12): 717. https:\/\/doi.org\/10.1007\/s00520-023-08160-0. (One of the first retrospective cohorts to evaluate alopecia outcomes in CDK 4\/6 therapy, providing practice-relevant epidemiologic data).","journal-title":"Support Care Cancer"},{"issue":"7","key":"1336_CR25","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","volume":"44","author":"M Silvestri","year":"2021","unstructured":"Silvestri M, Cristaudo A, Morrone A, et al. Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review. Drug Saf. 2021;44(7):725\u201332. https:\/\/doi.org\/10.1007\/s40264-021-01071-1.","journal-title":"Drug Saf"},{"issue":"3","key":"1336_CR26","first-page":"311","volume":"77","author":"DE Gerber","year":"2008","unstructured":"Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008;77(3):311\u20139.","journal-title":"Am Fam Physician"},{"issue":"2","key":"1336_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","volume":"72","author":"JB Macdonald","year":"2015","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part I: inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72(2):203\u201320. https:\/\/doi.org\/10.1016\/j.jaad.2014.07.032.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1336_CR28","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2007.13.2720","volume":"26","author":"R Lilenbaum","year":"2008","unstructured":"Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol. 2008;26(6):863\u20139. https:\/\/doi.org\/10.1200\/JCO.2007.13.2720.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1336_CR29","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1093\/annonc\/mdv390","volume":"26","author":"VR Belum","year":"2015","unstructured":"Belum VR, Marulanda K, Ensslin C, et al. Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol. 2015;26(12):2496\u2013502. https:\/\/doi.org\/10.1093\/annonc\/mdv390.","journal-title":"Ann Oncol"},{"issue":"3","key":"1336_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(11)70385-0","volume":"13","author":"T Ciuleanu","year":"2012","unstructured":"Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13(3):300\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(11)70385-0.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"1336_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0959-8049(09)70044-9","volume":"45","author":"S Segaert","year":"2009","unstructured":"Segaert S, Chiritescu G, Lemmens L, Dumon K, Van Cutsem E, Tejpar S. Skin toxicities of targeted therapies. Eur J Cancer. 2009;45(Suppl 1):295\u2013308. https:\/\/doi.org\/10.1016\/S0959-8049(09)70044-9.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1336_CR32","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.jaad.2017.01.060","volume":"88","author":"J Mounessa","year":"2023","unstructured":"Mounessa J, Caravaglio JV, Domozych R, et al. Commonly prescribed medications associated with alopecia. J Am Acad Dermatol. 2023;88(6):1326-37.e2. https:\/\/doi.org\/10.1016\/j.jaad.2017.01.060.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 3","key":"1336_CR33","doi-asserted-by":"publisher","first-page":"S350","DOI":"10.5021\/ad.2011.23.S3.S350","volume":"23","author":"BH Yang","year":"2011","unstructured":"Yang BH, Bang CY, Byun JW, et al. A case of cicatricial alopecia associated with erlotinib. Ann Dermatol. 2011;23(Suppl 3):S350\u20133. https:\/\/doi.org\/10.5021\/ad.2011.23.S3.S350.","journal-title":"Ann Dermatol"},{"issue":"8","key":"1336_CR34","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1365-2230.2010.03852.x","volume":"35","author":"R Hoekzema","year":"2010","unstructured":"Hoekzema R, Drillenburg P. Folliculitis decalvans associated with erlotinib. Clin Exp Dermatol. 2010;35(8):916\u20138. https:\/\/doi.org\/10.1111\/j.1365-2230.2010.03852.x.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"1336_CR35","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/j.1600-0560.2009.01275.x","volume":"36","author":"M Pongpudpunth","year":"2009","unstructured":"Pongpudpunth M, Demierre MF, Goldberg LJ. A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. J Cutan Pathol. 2009;36(12):1303\u20137. https:\/\/doi.org\/10.1111\/j.1600-0560.2009.01275.x.","journal-title":"J Cutan Pathol"},{"issue":"2","key":"1336_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","volume":"72","author":"JB Macdonald","year":"2015","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72(2):221\u201338. https:\/\/doi.org\/10.1016\/j.jaad.2014.07.033.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1336_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1203421.","journal-title":"N Engl J Med"},{"key":"1336_CR38","doi-asserted-by":"publisher","unstructured":"Rose L, Minta A, Plaza J, Cohn DE, Dulmage B. Mitogen-activated protein kinase inhibitor-induced inflammatory alopecia in woman with ovarian cancer. J Drugs Dermatol. 2024;23(4):e102\u20133. https:\/\/doi.org\/10.36849\/JDD.7802. Describes a rare inflammatory pattern of MEK inhibitor-induced alopecia, contributing to the differential diagnosis of drug-related hair loss","DOI":"10.36849\/JDD.7802"},{"issue":"1","key":"1336_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ. HER2-targeted therapies \u2013 a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33\u201348. https:\/\/doi.org\/10.1038\/s41571-019-0268-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1336_CR40","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641\u201361. https:\/\/doi.org\/10.1038\/s41573-023-00709-2. (Offers a review of antibody-drug conjugates, linking new HER2 and Trop-2 therapies to alopecia via cytotoxic payload mechanisms).","journal-title":"Nat Rev Drug Discov"},{"issue":"Sa","key":"1336_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1054\/ejon.2000.0071","volume":"4","author":"C B\u00f6hme","year":"2000","unstructured":"B\u00f6hme C. Anti-HER2 therapy: how to use Herceptin in clinical practice. Eur J Oncol Nurs. 2000;4(Sa):30\u20136. https:\/\/doi.org\/10.1054\/ejon.2000.0071.","journal-title":"Eur J Oncol Nurs"},{"issue":"7","key":"1336_CR42","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"issue":"12","key":"1336_CR43","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2115022.","journal-title":"N Engl J Med"},{"issue":"10371","key":"1336_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(22)02420-5. (Updated phase 3 trial results showing alopecia incidence from trastuzumab deruxtecan; relevant for informing patients about hair loss risks).","journal-title":"Lancet"},{"issue":"16","key":"1336_CR45","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"issue":"3","key":"1336_CR46","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","volume":"35","author":"LM Spring","year":"2024","unstructured":"Spring LM, Tolaney SM, Fell G, et al. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Ann Oncol. 2024;35(3):293\u2013301. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.018. (Recent trial highlights high alopecia incidence with sacituzumab govitecan, important for treatment planning and counseling).","journal-title":"Ann Oncol"},{"issue":"1","key":"1336_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","volume":"25","author":"A Muntyanu","year":"2021","unstructured":"Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV. Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg. 2021;25(1):59\u201376. https:\/\/doi.org\/10.1177\/1203475420943260.","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"1336_CR48","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/archderm.142.2.166","volume":"142","author":"SH Jaber","year":"2006","unstructured":"Jaber SH, Cowen EW, Haworth LR, et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol. 2006;142(2):166\u201372. https:\/\/doi.org\/10.1001\/archderm.142.2.166.","journal-title":"Arch Dermatol"},{"issue":"2","key":"1336_CR49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3747\/co.20.1265","volume":"20","author":"H Assi","year":"2013","unstructured":"Assi H, Wilson KS. Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases. Curr Oncol. 2013;20(2):165. https:\/\/doi.org\/10.3747\/co.20.1265.","journal-title":"Curr Oncol"},{"issue":"6","key":"1336_CR50","first-page":"E25","volume":"104","author":"DR Pearson","year":"2019","unstructured":"Pearson DR, Lewis K, Alkousakis T. Remote-onset alopecia areata attributed to ipilimumab. Cutis. 2019;104(6):E25\u20137.","journal-title":"Cutis"},{"key":"1336_CR51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","volume":"60","author":"VR Belum","year":"2016","unstructured":"Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12\u201325. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.010.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1336_CR52","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/bjd.15591","volume":"176","author":"T Ito","year":"2017","unstructured":"Ito T. Immune checkpoint inhibitor-associated alopecia areata. Br J Dermatol. 2017;176(6):1444\u20135. https:\/\/doi.org\/10.1111\/bjd.15591.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1336_CR53","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2018","unstructured":"Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345\u201361. https:\/\/doi.org\/10.1007\/s40257-017-0336-3.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1336_CR54","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/bjd.15237","volume":"176","author":"A Zarbo","year":"2017","unstructured":"Zarbo A, Belum VR, Sibaud V, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol. 2017;176(6):1649\u201352. https:\/\/doi.org\/10.1111\/bjd.15237.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1336_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14171","volume":"33","author":"L Antoury","year":"2020","unstructured":"Antoury L, Maloney NJ, Bach DQ, Goh C, Cheng K. Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: a review. Dermatol Ther. 2020;33(6): e14171. https:\/\/doi.org\/10.1111\/dth.14171.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1336_CR56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1200\/JOP.17.00038","volume":"14","author":"M Kruse","year":"2018","unstructured":"Kruse M, Abraham J. Management of chemotherapy-induced alopecia with scalp cooling. J Oncol Pract. 2018;14(3):149\u201354. https:\/\/doi.org\/10.1200\/JOP.17.00038.","journal-title":"J Oncol Pract"},{"issue":"5","key":"1336_CR57","doi-asserted-by":"publisher","first-page":"E442","DOI":"10.1002\/ijc.29115","volume":"136","author":"H Shin","year":"2015","unstructured":"Shin H, Jo SJ, Kim DH, Kwon O, Myung SK. Efficacy of interventions for prevention of chemotherapy-induced alopecia: a systematic review and meta-analysis. Int J Cancer. 2015;136(5):E442\u201354. https:\/\/doi.org\/10.1002\/ijc.29115.","journal-title":"Int J Cancer"},{"issue":"2","key":"1336_CR58","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10549-020-05968-w","volume":"185","author":"C Villarreal-Garza","year":"2021","unstructured":"Villarreal-Garza C, Mesa-Chavez F, Garza-Ledezma MRA, et al. Impact of chemotherapy regimen and sequence on the effectiveness of scalp cooling for alopecia prevention. Breast Cancer Res Treat. 2021;185(2):453\u20138. https:\/\/doi.org\/10.1007\/s10549-020-05968-w.","journal-title":"Breast Cancer Res Treat"},{"key":"1336_CR59","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S214907","author":"P Suchonwanit","year":"2019","unstructured":"Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019. https:\/\/doi.org\/10.2147\/DDDT.S214907.","journal-title":"Drug Des Devel Ther"},{"key":"1336_CR60","unstructured":"Patel P, KD NT. Minoxidil. In:\u00a0StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan\u2013. Available from:\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482378\/"},{"issue":"1","key":"1336_CR61","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0190-9622(96)90500-9","volume":"35","author":"M Duvic","year":"1996","unstructured":"Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35(1):74\u20138. https:\/\/doi.org\/10.1016\/S0190-9622(96)90500-9.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1336_CR62","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/jamadermatol.2018.5071","volume":"155","author":"A Freites-Martinez","year":"2019","unstructured":"Freites-Martinez A, Chan D, Sibaud V, et al. Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol. 2019;155(6):724\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5071.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1336_CR63","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1111\/ajd.12350","volume":"57","author":"X Yang","year":"2016","unstructured":"Yang X, Thai KE. Treatment of permanent chemotherapy-induced alopecia with low dose oral minoxidil. Australas J Dermatol. 2016;57(4):e130\u20132. https:\/\/doi.org\/10.1111\/ajd.12350.","journal-title":"Australas J Dermatol"},{"key":"1336_CR64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jdcr.2022.01.035","volume":"22","author":"A Lyakhovitsky","year":"2022","unstructured":"Lyakhovitsky A, Segal O, Maly A, Zlotogorski A, Barzilai A. Permanent chemotherapy-induced alopecia after hematopoietic stem cell transplantation treated with low-dose oral minoxidil. JAAD Case Rep. 2022;22:64\u20137.","journal-title":"JAAD Case Rep"},{"issue":"5","key":"1336_CR65","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jaad.2022.12.005","volume":"88","author":"J Kang","year":"2023","unstructured":"Kang J, Lee JW, Kwon O. Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: a retrospective cohort study. J Am Acad Dermatol. 2023;88(5):1170\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.005. (Provides real-world evidence on the use of oral minoxidil in cancer-related alopecia, which is especially valuable given limited data).","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1336_CR66","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s00403-023-02660-z","volume":"315","author":"A Minta","year":"2023","unstructured":"Minta A, Park C, Rose L, Trovato S, Dulmage B. Retrospective review of oral and topical minoxidil for cancer treatment-induced hair loss. Arch Dermatol Res. 2023;315(9):2613\u20135. https:\/\/doi.org\/10.1007\/s00403-023-02660-z. (Compares oral vs. topical minoxidil, supporting its emerging role in CRA management and patient-centered decision making).","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"1336_CR67","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.3390\/curroncol30040275","volume":"30","author":"TC Wikramanayake","year":"2023","unstructured":"Wikramanayake TC, Haberland NI, Akhundlu A, Laboy Nieves A, Miteva M. Prevention and treatment of chemotherapy-induced alopecia: what is available and what is coming? Curr Oncol. 2023;30(4):3609\u201326. https:\/\/doi.org\/10.3390\/curroncol30040275. (Comprehensive review of current and pipeline therapies for CIA; provides a summary of what is available and what is next).","journal-title":"Curr Oncol"},{"key":"1336_CR68","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2147\/CCID.S398950","volume":"16","author":"C Wang","year":"2023","unstructured":"Wang C, Du Y, Bi L, Lin X, Zhao M, Fan W. The efficacy and safety of oral and topical spironolactone in androgenetic alopecia treatment: a systematic review. Clin Cosmet Investig Dermatol. 2023;16:603\u201312. https:\/\/doi.org\/10.2147\/CCID.S398950. (While focused on androgenetic alopecia, it evaluates spironolactone\u2019s potential, indirectly relevant to CRA management in hormone-sensitive cancers).","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"1336_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15321","volume":"35","author":"DA Aguilar Medina","year":"2022","unstructured":"Aguilar Medina DA, Cazar\u00edn J, Maga\u00f1a M. Spironolactone in dermatology. Dermatol Ther. 2022;35(5): e15321. https:\/\/doi.org\/10.1111\/dth.15321.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1336_CR70","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12915","volume":"32","author":"A Sharma","year":"2019","unstructured":"Sharma A, Goren A, Dhurat R, et al. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatol Ther. 2019;32(3): e12915. https:\/\/doi.org\/10.1111\/dth.12915.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1336_CR71","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jaad.2011.06.005","volume":"66","author":"S Smith","year":"2012","unstructured":"Smith S, Fagien S, Whitcup SM, et al. Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol. 2012;66(5):801\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2011.06.005.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1336_CR72","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1038\/jidsymp.2013.30","volume":"16","author":"GS Ahluwalia","year":"2013","unstructured":"Ahluwalia GS. Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss. J Investig Dermatol Symp Proc. 2013;16(1):S73-6. https:\/\/doi.org\/10.1038\/jidsymp.2013.30.","journal-title":"J Investig Dermatol Symp Proc."},{"issue":"5","key":"1336_CR73","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/bjd.13443","volume":"172","author":"DA Glaser","year":"2015","unstructured":"Glaser DA, Hossain P, Perkins W, et al. Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial. Br J Dermatol. 2015;172(5):1384\u201394. https:\/\/doi.org\/10.1111\/bjd.13443.","journal-title":"Br J Dermatol"},{"key":"1336_CR74","doi-asserted-by":"publisher","unstructured":"Baiyasi M, St Claire K, Hengy M, et al. Eyelash serums: a comprehensive review. J Cosmet Dermatol. 2024;23(7):2328\u201344. https:\/\/doi.org\/10.1111\/jocd.16278. (Evaluates prostaglandin-based eyelash serums; increasingly relevant for patients experiencing chemotherapy-induced eyelash loss).","DOI":"10.1111\/jocd.16278"},{"issue":"5","key":"1336_CR75","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00520-023-07743-1","volume":"31","author":"J Lodewijckx","year":"2023","unstructured":"Lodewijckx J, Robijns J, Claes M, et al. The use of photobiomodulation therapy for the management of chemotherapy-induced alopecia: a randomized, controlled trial (HAIRLASER trial). Support Care Cancer. 2023;31(5):269. https:\/\/doi.org\/10.1007\/s00520-023-07743-1. (Presents randomized trial data on photobiomodulation therapy a promising adjunct or alternative for CRA).","journal-title":"Support Care Cancer"},{"issue":"1","key":"1336_CR76","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jaad.2019.12.027","volume":"88","author":"E Tkachenko","year":"2023","unstructured":"Tkachenko E, Okhovat JP, Manjaly P, et al. Complementary and alternative medicine for alopecia areata: a systematic review. J Am Acad Dermatol. 2023;88(1):131\u201343. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.027. (While focused on alopecia areata, this systematic review includes alternative therapies applicable to patient preferences in CRA).","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1336_CR77","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000492035","volume":"5","author":"AM Hosking","year":"2019","unstructured":"Hosking AM, Juhasz M, Atanaskova Mesinkovska N. Complementary and alternative treatments for alopecia: a comprehensive review. Skin Appendage Disord. 2019;5(2):72\u201389. https:\/\/doi.org\/10.1159\/000492035.","journal-title":"Skin Appendage Disord"},{"issue":"12","key":"1336_CR78","first-page":"15","volume":"8","author":"G Ablon","year":"2015","unstructured":"Ablon G, Dayan S. A randomized, double-blind, placebo-controlled, multi-center, extension trial evaluating the efficacy of a new oral supplement in women with self-perceived thinning hair. J Clin Aesthet Dermatol. 2015;8(12):15\u201321.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4","key":"1336_CR79","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4103\/0974-7753.171573","volume":"7","author":"RL Rizer","year":"2015","unstructured":"Rizer RL, Stephens TJ, Herndon JH, et al. A marine protein-based dietary supplement for subclinical hair thinning\/loss: results of a multisite, double-blind, placebo-controlled clinical trial. Int J Trichology. 2015;7(4):156\u201366. https:\/\/doi.org\/10.4103\/0974-7753.171573.","journal-title":"Int J Trichology"},{"key":"1336_CR80","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/841570","volume":"2015","author":"G Ablon","year":"2015","unstructured":"Ablon G. A 3-month, randomized, double-blind, placebo-controlled study evaluating the ability of an extra-strength marine protein supplement to promote hair growth and decrease shedding in women with self-perceived thinning hair. Dermatol Res Pract. 2015;2015: 841570. https:\/\/doi.org\/10.1155\/2015\/841570.","journal-title":"Dermatol Res Pract"},{"issue":"5","key":"1336_CR81","first-page":"558","volume":"17","author":"G Ablon","year":"2018","unstructured":"Ablon G, Kogan S. A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. J Drugs Dermatol. 2018;17(5):558\u201365.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1336_CR82","doi-asserted-by":"publisher","first-page":"55","DOI":"10.36849\/JDD.5701","volume":"20","author":"G Ablon","year":"2021","unstructured":"Ablon G, Kogan S. A randomized, double-blind, placebo-controlled study of a nutraceutical supplement for promoting hair growth in perimenopausal, menopausal, and postmenopausal women with thinning hair. J Drugs Dermatol. 2021;20(1):55\u201361. https:\/\/doi.org\/10.36849\/JDD.5701.","journal-title":"J Drugs Dermatol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01336-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01336-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01336-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:57:49Z","timestamp":1757235469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01336-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":82,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01336-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"9 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}